By Chris Wack

Opus Genetics shares were up 22% at $1.21, after the company said it saw positive topline results from a pivotal Phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

The biopharmaceutical company said the treatment is meant to help patients who undergo keratorefractive eye procedures, such as laser-assisted in situ keratomileusis.

According to the company, phentolamine ophthalmic solution 0.75% is designed to reduce pupil diameter through a sympatholytic mechanism of action that avoids engaging the ciliary muscle, potentially reducing risks such as retinal tears or detachment associated with older parasympathomimetic agents. These disturbances can significantly impair night driving and daily functioning in dim environments.

The study met its primary endpoint of a gain of three lines--or 15 letters--or more of distance vision improvement on a low-contrast chart in low light conditions after 15 days of dosing.

Opus said the study showed a safety profile consistent with previous studies, with no new safety signals identified. No evidence of tachyphylaxis was observed in this study over the six-week period.

The stock hit its 52-week low of 65 cents on April 10, and is down 27% in the past 12 months.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 02, 2025 10:51 ET (14:51 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.